Post 01: Before You Spend a Dollar on Quantum, Answer This
Three executives at three pharmas got the same quantum vendor pitch last quarter. One signed a three-year deal. One asked for a six-month pilot. One walked. None of them was wrong
The first quantum computing decision a drug development executive has to make is not technical. It is identity.
I have watched three CMOs at three different pharmas sit through the same quantum vendor pitch in the past quarter. One signed a three-year strategic partnership. One agreed to a six-month scoped pilot. One thanked the vendor and walked. All three made defensible decisions. Their pipelines were different. Their boards were different. Their portfolios had different chemotypes, different timelines, different cash positions. The quantum question landed differently on each desk because the prior question — “what kind of R&D organization are we?” — had been answered differently long before the vendor showed up.
Most quantum-strategy advice in pharma skips this step. It tells you what quantum can do, what it cannot do, who is partnering with whom. Useful enough. But it assumes you have already answered the only question that matters: where does your company sit on the early-adopter-to-skeptic curve, and is that position aligned with your board?
Three archetypes. Pick one honestly.
The early adopter. This is the company that builds an internal quantum capability before the technology is mature, accepts that some of the early bets will be wrong, and treats the cost as the price of optionality. Boehringer Ingelheim with Google. Roche with Cambridge Quantum. Merck with HQS. The investment thesis is straightforward: when fault-tolerant quantum computing matures, the companies that already have hybrid workflows and quantum-literate teams will move faster than the ones starting from zero. The economic case is harder. Five years of internal quantum spend with no validated commercial output is hard to defend in a year when the board wants pipeline focus.
You should be an early adopter if your pipeline contains enough strongly correlated chemistry — transition-metal catalysis, metalloenzyme inhibitors, photoredox biology — to justify the bet on its own scientific merit, and your board has the patience for a multi-year capability play. If you are an early adopter and your board does not have that patience, you are an early adopter who is about to disappoint your board.
The fast follower. This is the company that watches the early adopters carefully, runs scoped pilots with one or two vendors per year, and waits for a clear advantage signal before committing internal capability. Most large pharmas are quietly fast followers, even when their press releases sound like early-adopter language. The discipline of the fast follower is the willingness to spend ten to twenty million dollars a year on quantum exploration and walk away from any pilot that does not produce a defensible result by month nine. The discipline is also the willingness to look slow when an early-adopter peer announces something that turns out to be marketing.
You should be a fast follower if your pipeline could plausibly benefit from quantum in two or three areas, your board wants quarterly updates with concrete milestones, and you have the operational maturity to run vendor pilots without becoming captive to them. Most companies that should be fast followers convince themselves they are early adopters. The cost of that mistake is paid in the discovery budget two years later.
The patient skeptic. This is the company that reads the literature, attends one or two industry forums a year, has a single named executive responsible for quantum-readiness, and otherwise spends nothing. The patient skeptic is not anti-quantum. They have looked at their own pipeline, decided that quantum will not move the needle on the molecules they actually care about for at least seven to ten years, and made a deliberate decision to deploy that capital elsewhere. Cell and gene therapy companies, biologics-focused mid-caps, generics manufacturers, and any company whose chemistry is dominated by problems classical methods already solve adequately should probably be patient skeptics.
You should be a patient skeptic if your pipeline does not contain the chemotypes where quantum has a defensible near-term case, your board has more pressing capability gaps elsewhere, and you can credibly explain to your CSO why “we are watching” is a complete answer. The mistake patient skeptics make is forgetting to maintain the watch. The technology is moving. The decision to wait should be revisited every twelve months, not made once and filed.
The diagnostic is uncomfortable on purpose. It is meant to surface the gap between the archetype your company actually fits and the archetype your strategy deck claims you are. In my experience, that gap is the single most expensive misalignment in the pharma technology stack — more expensive than the quantum spend itself.
A short version of the diagnostic. Answer honestly.
How much of your active pipeline involves chemistry where DFT or coupled-cluster methods break down — transition metals, multireference systems, strongly correlated electrons? If the answer is “a lot,” lean toward early adopter. If “some,” fast follower. If “almost none,” patient skeptic.
How much patience does your board have for capability investments without near-term pipeline contribution? If three years or more, early adopter is defensible. If twelve to eighteen months, fast follower. If “we have other priorities,” patient skeptic.
How much do you trust your CSO to walk away from a vendor pilot that is not delivering? If completely, fast follower works. If you would worry about sunk-cost dynamics, lean patient skeptic until your governance is stronger.
That is the entire framework. There is more to say about each archetype — what to spend, who to hire, which partnerships to consider — and the next nineteen posts in this series will say it. But none of that material matters until you have answered the question on this page.
The decision this post forces: which archetype are you, and is that aligned with what your board actually wants? If you cannot answer both halves of that question with confidence, your quantum strategy does not exist yet — you have a quantum vocabulary, which is different.
The trigger to revisit: twelve months from today, or sooner if a peer in your therapeutic area announces a quantum result that would, if true, change your pipeline economics.
#QuantumComputing #DrugDiscovery #ClinicalTrials #Biopharma
🔗 Drug Developer Newsletter → [Subscribe on LinkedIn https://www.linkedin.com/build-relation/newsletter-follow?entityUrn=7334337397922430977]
🔗 Clinical Trial Newsletter → [Subscribe on LinkedIn https://www.linkedin.com/build-relation/newsletter-follow?entityUrn=7347268184502112256 ]